Geron Corporation

Case Overview
Status: | Status: Investigating |
Company Name: | Company Name: Geron Corporation |
Ticker: | Ticker: GERN |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP is investigating potential claims against Geron Corporation (“Geron” or the “Company”) (NASDAQ:GERN). The investigation concerns whether Geron and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
On February 26, 2025, Geron announced its financial results for the fourth year and full year 2024. During a related earnings call, Geron’s executives said that the Company has “observed flat revenue trends over the last few months” for its recently approved blood disorder drug, Rytelo. On this news, the price of Geron shares declined by $0.76 per share, or approximately 32%, from $2.37 per share on February 25, 2025, to close at $1.61 on February 26, 2025.
On February 26, 2025, Geron announced its financial results for the fourth year and full year 2024. During a related earnings call, Geron’s executives said that the Company has “observed flat revenue trends over the last few months” for its recently approved blood disorder drug, Rytelo. On this news, the price of Geron shares declined by $0.76 per share, or approximately 32%, from $2.37 per share on February 25, 2025, to close at $1.61 on February 26, 2025.